The European Union’s medicine regulator on Thursday approved the use of the conditional Covid-19 antiviral pill of Pfizer Inc. for the treatment of adults at risk of serious diseases, as the region strives to increase its arsenal to combat the Omicron variant.
The approval of the European Medicines Agency (EMAfor its acronym in English) allows EU member states to use the drug after the regulator at the end of last year provided guidance for its emergency use.
Italy, Germany and Belgium are among the EU countries that bought the drug.
In December, the United States approved the use of Paxlovid and the similar drug Merckmolnupiravir.
Merck’s pill is also being reviewed in the EU, but approval is taking longer because the company reviewed data from its trials in November, saying the drug was significantly less effective than previously thought.
Reference-www.eleconomista.com.mx